📅 PUBMED DAILY TRIAGE — 2026-03-25
Window: 2026-03-24T00:00:00Z → 2026-03-25T23:59:59Z (CRDT, 48h expansion) Topics scanned: 10 | Articles reviewed: 16 High priority: 3 | Standard: 10 | Low/archive: 3 | Unsolicited finds: 2 Run status: SUCCESS
🔴🟠 HIGH PRIORITY
TR-2026-03-25-010 · PMID 41873944 · Repurposing HER2 IHC: Pan-HER2 and Low-HER2 · 8/10 · HER2-low testing is an immediate, lab-actionable paradigm shift driven by ADC therapy approvals (T-DXd); affects pathology workflow and treatment eligibility across breast, gastric, and other cancers. [🟢 NEAR_TERM_IMPLEMENTABLE]
TR-2026-03-25-003 · PMID 41875890 · Mazdutide 9 mg in Chinese adults with obesity (BMI ≥30) without diabetes: Phase 2 RCT · 8/10 · First Phase 2 RCT data for a dual GLP-1/glucagon receptor agonist at 9 mg in a large non-Western population; extends the GLP-1 class into a major underrepresented group with potentially superior efficacy profile. [🟠 NOVEL_TREATMENT]
TR-2026-03-25-008 · PMID 41876352 · Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis (Kantarjian/MD Anderson) · 7/10 → promoted by NEAR_TERM_IMPLEMENTABLE flag · Dose-optimization pooled analysis for a widely-used TKI with potential to reduce toxicity without sacrificing efficacy in CML; directly actionable for treating physicians. [🟢 NEAR_TERM_IMPLEMENTABLE]
Note: TR-2026-03-25-008 score is 7 (STANDARD by score alone) but qualifies as HIGH by NEAR_TERM_IMPLEMENTABLE flag and clinical significance. Promoting to HIGH section per pipeline convention for flag override. Will emit 3 alerts total (≤5 cap).
🟢⚪ STANDARD
| Record ID | PMID | Title | Score | Category |
|---|---|---|---|---|
| TR-2026-03-25-001 | 41876135 | IL-12-secreting CAR-T cells reprogram TME in glioblastoma | 7/10 | Treatment Innovation |
| TR-2026-03-25-002 | 41876134 | Nrf2 inhibition enhances immunotherapy efficacy in HCC | 6/10 | Treatment Innovation |
| TR-2026-03-25-004 | 41874885 | Nanobiosensors for early cancer detection: comprehensive review | 5/10 | Early Detection |
| TR-2026-03-25-005 | 41875196 | MPCI: novel DNA methylation metric for NGS/cfDNA analysis | 6/10 | Diagnostics / Genomics |
| TR-2026-03-25-006 | 41873502 | Pleural fluid biomarkers for malignant pleural effusion & lung cancer | 6/10 | Diagnostics |
| TR-2026-03-25-007 | 41876210 | QoL and symptoms in AML with early palliative care (real-world) | 6/10 | Public Health |
| TR-2026-03-25-009 | 41876379 | SPTCL: SEER database characteristics, treatment, prognosis | 6/10 | Diagnostics (rare lymphoma) |
| TR-2026-03-25-011 | 41876396 | Label-free intraoperative breast cancer diagnosis via polarization microscopy | 6/10 | Diagnostics |
| TR-2026-03-25-012 | 41876208 | Physical activity patterns and MACE in adults with hypertension | 6/10 | Prevention |
| TR-2026-03-25-013 | 41876404 | Senescence-IL-17A-EMT circuit in age-related cataracts | 4/10 | Aging/Other |
| TR-2026-03-25-014 | 41875884 | Inflammatory pathways driving MASH (Cell Metabolism review) | 5/10 | Drug Development |
| TR-2026-03-25-015 | 41876291 | EULAR recommendations for Behçet's syndrome: 2025 update | 7/10 | Rare Disease / Guideline |
💡 UNSOLICITED FINDS
- TR-2026-03-25-015 · PMID 41876291 · EULAR 2025 Behçet's syndrome guideline update — sentinel scan; confirmed rare disease watchlist match on review. Score 7/10. [🟡 UNDERSERVED_POPULATION]
- TR-2026-03-25-016 · PMID 41876152 · MR-PREG cohort collaboration profile (Mendelian randomization for pregnancy outcomes) — infrastructure paper; out-of-watchlist; low score (3/10). [⬜ NONE]
📊 TODAY'S BREAKDOWN
By research category:
- Diagnostics: 5
- Treatment Innovation: 4
- Early Detection: 2
- Prevention: 1
- Public Health: 2
- Drug Development: 1
- Genomics/Precision Medicine: 1 (dual-matched)
By evidence maturity:
- Exploratory: 7
- Validated: 7
- Potentially Practice-Changing: 2
By watchlist topic:
- Hematologic malignancies: 3
- Early cancer detection (liquid biopsy/ctDNA/cfDNA): 3
- Novel therapeutics (immunotherapy, CAR-T): 3
- Cardiovascular-metabolic (GLP-1/SGLT2): 3
- Precision oncology/genomics: 2
- Rare diseases: 2
- AI/ML diagnostics: 2
- Aging/longevity: 1
- CBC/hematology ML: 0 (overlap with AI/ML topic)
- Sentinel scan (unsolicited): 2
By source type:
- Peer reviewed: 16 | Preprint: 0
🔧 RUN NOTES
- 48h window expansion triggered: CRDT single-day search (2026-03-25) returned 0 results across all topics — consistent with CRDT indexing lag noted in 2026-03-24 run. Expanded window to 2026-03-24:2026-03-25 per protocol.
- Deduplication applied: All 26 previously emitted PMIDs from state.json filtered. Net new: 16 articles.
- CBC/ML topic: No unique new records; all matched PMIDs overlapped with the AI/ML diagnostics topic search results.
- AI/ML topic: 112 raw results retrieved; top 25 scanned; 3 kept after relevance filtering and dedup. High-volume topic — no truncation concerns with current cap.
- Aging topic: 220 raw results; top 20 scanned; 1 kept (aging-senescence cataracts paper); remaining were orthopedic/geriatric/non-watchlist content.
- Sentinel scan: 249 raw results; top 15 scanned; 2 unique unsolicited finds retained (EULAR guideline, MR-PREG collaboration).
- Data quality: All records abstract-only; no PMC full text retrieved in this run. classification_confidence = high for most (PMID + abstract + study design identifiable); medium for TR-2026-03-25-011 (ex vivo study design ambiguity).
- HIGH priority alert override: TR-2026-03-25-008 (dasatinib pooled analysis) score = 7 but promoted to HIGH alert section via NEAR_TERM_IMPLEMENTABLE flag given MD Anderson provenance and direct CML practice relevance. Alert count = 3 (within 5-article cap).